Novartis to Build 7 New U.S. Facilities

Novartis, a Swiss pharmaceutical giant, has announced a $23 billion investment to expand its U.S. operations over the next five years, amid President Trump's tariff threats on imported pharmaceuticals. The investment includes building seven new facilities, including a research hub in San Diego and six manufacturing plants, with the aim of producing all of Novartis' key medicines for the U.S. domestically. This expansion will create approximately 1,000 direct jobs and an additional 4,000 jobs nationwide. The initiative is part of a broader strategy to solidify Novartis' position in the U.S. market and aligns with other pharmaceutical companies' recent commitments to increase U.S. manufacturing. Trump's tariff threats have pressured drugmakers to bolster domestic production, though Novartis claims the tariffs are not the primary factor behind the investment. Overall, Novartis plans to spend nearly $50 billion on U.S. operations over the next five years.